Company Filing History:
Years Active: 2016-2025
Title: The Innovative Contributions of Ali El-Tayeb
Introduction
Ali El-Tayeb is a prominent inventor based in Bonn, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target central nervous system disorders. With a total of 6 patents to his name, El-Tayeb's work is paving the way for new treatments in this critical area of medicine.
Latest Patents
Among his latest patents, El-Tayeb has developed N-(phenyl)-indole-3-sulfonamide derivatives and related compounds that serve as GPR17 modulators for treating CNS disorders such as multiple sclerosis. These compounds include N-(phenyl)-1H-indole-3-sulfonamide and N-(phenyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide derivatives, which are substituted at the 1- and 6-positions of the respective moieties. The compounds exhibit GPR17 modulating properties, making them useful for preventing and treating myelinating disorders, particularly multiple sclerosis. Additionally, he has disclosed sulfonamide compounds with similar GPR17 modulating properties, aimed at treating a variety of CNS diseases.
Career Highlights
El-Tayeb has worked with notable companies in the pharmaceutical industry, including UCB Pharma GmbH and Crozet Medical GmbH. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research in CNS disorders.
Collaborations
Throughout his career, El-Tayeb has collaborated with esteemed colleagues such as Christa E. Mueller and Joerg Hockemeyer. These partnerships have further enhanced his research and development efforts in the field.
Conclusion
Ali El-Tayeb's innovative work in developing GPR17 modulators represents a significant advancement in the treatment of CNS disorders. His contributions are vital for the ongoing research and development of effective therapies for conditions like multiple sclerosis.